Fig. 2From: Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?Waterfall plot of the percent change in tumor size (a) and density (b) at the first evaluation after sunitinib treatmentBack to article page